RESUMO
Four hundred and eighty Chinese subjects with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) were enrolled in a multicenter, double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) 10 mg once daily. There was a significant difference in reduction of serum hepatitis B virus (HBV) DNA after 12 weeks between subjects who received ADV and those who received the placebo (3.4 and 0.1 log10 copies/mL, respectively, P < .001). Further reductions in serum HBV DNA and increases in the proportion of subjects with an HBV DNA level of at most 10(5) copies/mL, with HBV DNA undetectable, and with ALT normalization were observed in ADV-treated subjects at week 52 (median HBV DNA reduction of 4.5 log(10) copies/mL, 67% with HBV DNA Assuntos
Adenina/análogos & derivados
, Antivirais/uso terapêutico
, Antígenos E da Hepatite B/imunologia
, Vírus da Hepatite B/imunologia
, Hepatite B Crônica/tratamento farmacológico
, Organofosfonatos/uso terapêutico
, Adenina/uso terapêutico
, Adolescente
, Adulto
, China/epidemiologia
, DNA Viral/genética
, Método Duplo-Cego
, Feminino
, Seguimentos
, Vírus da Hepatite B/genética
, Hepatite B Crônica/epidemiologia
, Hepatite B Crônica/virologia
, Humanos
, Imunossupressores
, Incidência
, Masculino
, Pessoa de Meia-Idade
, Resultado do Tratamento